TMEM161A

Across TCGA pan-cancer cohorts, TMEM161A RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TMEM161A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TMEM161A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM161A is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, COAD, and HNSC are the cancer types where TMEM161A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM161A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+0.828	<.001	12	view →
COAD	Female	All	+1.631	<.001	11	view →
HNSC	Male	III,IV	+0.913	<.001	11	view →
KIRP	Male	II,III,IV	+0.717	<.001	11	view →
STAD	Male	III,IV	+1.526	<.001	9	view →
LIHC	Male	II,III,IV	+1.295	<.001	9	view →
THCA	All	IV	−1.092	<.001	9	view →
BLCA	Male	All	+1.048	<.001	9	view →
READ	All	All	+1.356	<.001	7	view →
LUSC	All	II,III,IV	+0.884	<.001	7	view →
UCEC	All	All	+0.527	.002	6	view →
BRCA	All	All	+0.280	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TMEM161A–KIRC

Open the KIRC breakdown →